Transplantation tolerance induced by "mega dose" CD34+ cell transplants

被引:65
作者
Reisner, Y [1 ]
Martelli, MF
机构
[1] Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel
[2] Univ Perugia, Dept Hematol & Clin Immunol, Perugia, Italy
关键词
mega dose; haploidentical; GVHD; veto activity;
D O I
10.1016/S0301-472X(99)00132-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Early studies in murine models and more recent clinical data in heavily pretreated leukemia patients have shown that escalation of hematopoietic progenitor cells can overcome major genetic barriers and enable rapid and durable engraftment of haploidentical 3-loci mismatched transplants without graft-versus-host disease. In vitro studies suggest that veto cells within the progenitors population most likely mediate this facilitating effect. Leukemia relapse is relatively Low in patients with acute myeloid leukemia (AML) but is greater in adults with acute Lymphoblastic leukemia (ALL), Donor NK cells most likely mediate the resistance to relapse in patients with AML who are recipients of haploidentical transplants. Immune reconstitution in adults but not in children is slow as in adult recipients of HLA matched unrelated bone marrow transplants. The "mega dose" concept was also shown recently to be useful for tolerance induction in sublethally irradiated mice, so as to effectively overcome the marked resistance presented by the large number of lymphocytes surviving the sublethal conditioning. Thus, allogeneic chimeras generated by transplantation of large doses of Scal(+)Lin(-) cells, permanently accept allogeneic donor type skin grafts. However, the numbers required to attain this desirable goal may not be easily collected from human donors. Nonalloreactive T cells synergize with murine Scal(+)Lin(-) cells and might, therefore, enable achievement of engraftment of haploidentical transplants in sublethally conditioned patients. (C) 2000 International Society for Experimental Hematology. Published by Elsevier Science Inc.
引用
收藏
页码:119 / 127
页数:9
相关论文
共 49 条
[21]  
KAUFMAN CL, 1994, BLOOD, V84, P2436
[22]   GRAFT-REJECTION IN RECIPIENTS OF T-CELL-DEPLETED HLA-NONIDENTICAL MARROW TRANSPLANTS FOR LEUKEMIA - IDENTIFICATION OF HOST-DERIVED ANTIDONOR ALLOCYTOTOXIC LYMPHOCYTES-T [J].
KERNAN, NA ;
FLOMENBERG, N ;
DUPONT, B ;
OREILLY, RJ .
TRANSPLANTATION, 1987, 43 (06) :842-847
[23]   ANALYSIS OF 462 TRANSPLANTATIONS FROM UNRELATED DONORS FACILITATED BY THE NATIONAL-MARROW-DONOR-PROGRAM [J].
KERNAN, NA ;
BARTSCH, G ;
ASH, RC ;
BEATTY, PG ;
CHAMPLIN, R ;
FILIPOVICH, A ;
GAJEWSKI, J ;
HANSEN, JA ;
HENSLEEDOWNEY, J ;
MCCULLOUGH, J ;
MCGLAVE, P ;
PERKINS, HA ;
PHILLIPS, GL ;
SANDERS, J ;
STRONCEK, D ;
THOMAS, ED ;
BLUME, KG .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (09) :593-602
[24]  
LAPIDOT T, 1988, J IMMUNOL, V141, P2619
[25]  
LAPIDOT T, 1989, BLOOD, V73, P2025
[26]  
LAPIDOT T, 1992, BLOOD, V80, P2406
[27]  
LAPIDOT T, 1987, BLOOD, V70, pA309
[28]   Natural killer cells weakly resist engraftment of allogeneic, long-term, multilineage-repopulating hematopoietic stem cells [J].
Lee, LA ;
Sergio, JJ ;
Sykes, M .
TRANSPLANTATION, 1996, 61 (01) :125-132
[29]  
MARTIN PJ, 1990, BONE MARROW TRANSPL, V6, P283
[30]   DONOR CD8 CELLS PREVENT ALLOGENEIC MARROW GRAFT-REJECTION IN MICE - POTENTIAL IMPLICATIONS FOR MARROW TRANSPLANTATION IN HUMANS [J].
MARTIN, PJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (02) :703-712